dbACP: A Comprehensive Database of Anti-Cancer Peptides

185 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00320 [A18K]OCN-3N GIFDVLKNLAKGVITSLKS Derivatives of ocellatin-3N Membranolytic mechanism Not specified MDA-MB-231 Breast adenocarcinoma LC50 : 12-20 μM
dbacp00434 [D4K,A18K]OCN-3N GIFKVLKNLAKGVITSLKS Derivatives of ocellatin-3N Membranolytic mechanism Not specified MDA-MB-231 Breast adenocarcinoma LC50 : 12-20 μM
dbacp00437 [D4K]OCN-3N GIFKVLKNLAKGVITSLAS Derivatives of ocellatin-3N Not specified Lactate dehydrogenase (LDH) assay MDA-MB-231 Breast adenocarcinoma LC50 : 12-20 μM
dbacp00742 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 39 µM
dbacp00743 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 29 µM
dbacp00744 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 16 µM
dbacp00755 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 18 µM
dbacp00756 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 12 µM
dbacp00757 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 10 µM
dbacp00982 Adenoregulin GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV South American frog, Giant leaf frog Cell membrane disintegration LDH leakage assay MDA-MB-231 Breast cancer GI50 : 8.06 ± 0.50 µM
dbacp00991 AKPF dimer, Smac-1 (AKPF-NH2)2 SMAC Inducing apoptosis Not specified MDA-MB-231 Not specified IC50 : 3.93 ± 1.1 nM
dbacp01007 Alyteserin-2 ILGKLLSTAAGLLSNL Common midwife toad Cell penetration Cytotoxicity assay MDA-MB-231 Breast adenocarcinoma LC50 : 20 µM
dbacp01186 APQQ NA Synthetic construct Cell metatstasis inhibition Transwell assay MDA-MB-231 Breast cancer Not found
dbacp01355 Aurein-2.7 GLFDIAKKVIGVIGSL Southern bell frog Cell membrane disintegration One-dose and five-dose assay MDA-MB-231/ATCC Breast cancer IC50 : 5 μM
dbacp01452 Bassianolide nonribosomal cyclodepsipeptide synthetase MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL White muscardine disease fungus Cell apoptosis Not specified MDA-MB-231 Breast cancer Not found
dbacp01455 Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL White muscardine disease fungus Cell apoptosis Not specified MDA-MB-231 Breast cancer Not found
dbacp01892 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 32.5 ± 0.5 μM
dbacp01897 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 31.2 ± 5 μM
dbacp01902 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.0 ± 7 μM
dbacp01907 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.7 ± 3 μM
dbacp01947 Brevinin-1RL1 FFPLIAGLAARFLPKIFCSITKRC Not found Inducing apoptosis Cell death assay MDA-MB-231 Not specified IC50 : 5.44 ± 0.33 μM
dbacp01997 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 11.3 µg/ml
dbacp02055 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MDA-MB-231 Not specified IC50 : 11.3 µg/ml
dbacp02297 Carcinoembryonic antigen glypican-3 GPC3(298-306) EYILSLEEL Carcinoembryonic antigen glypican-3 GPC3(298-306) Immune response to tumor cell recognition Cytotoxicity assay MDA-MB-231 Not specified Not found
dbacp02476 Chickpea peptide ADLPGLK Plant sources Inducing apoptosis SRB assay MDA-MB-231 Human endometrial cancer IIC50 : 107.2 ± 1.62µM
dbacp02599 Cyclosaplin RLGDGCTR Not found Apoptosis DNA fragmentation assay MDA-MB-231 Breast cancer IC50 : 2.06 µg/mL
dbacp02622 D-K6L9 LKlLKKLlkKLLkLL Not found Necrosis; Membrane disruption Enzyme Immunoassay (EIA) MB-231 Prostate cancer LC50 : 3 µMol/L
dbacp02656 Dermaseptin-B2 GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV Giant leaf frog Immunomodulatory properties Cytotoxicity assays, Cell Titer-Glo Luminescent Cell viability assay MDA-MB-231 Breast adenocarcinoma LC50 : < 12 μM
dbacp02826 EGFR-lytic YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK Synthetic Peptide Cell membrane lysis ELISA MDA-MB-231 Breast cancer IC50 : 0.12 µM
dbacp02827 EGFR-lytic YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK Synthetic Peptide Cell membrane lysis ELISA MDA-MB-231 Breast cancer IC50 : 0.46 µM
dbacp02956 Figainin 2BN FLGVALKLGKVLGKALLPLASSLLHSQ Norepinephrine-stimulated skin secretion, the Giant Gladiator Treefrog, the Rusty Treefrog, Trinidad, South America Cell membrane penetration Not specified MDA-MB-231 Breast adenocarcinoma LC50 : 7-14 µM
dbacp02959 Figainin 2PL FLGTVLKLGKAIAKTVVPMLTNAMQPKQ Skin secretions, the bananatree dwelling frog, Trinidad, South America Membrane disruption Not specified MDA-MB-231 Not found LC50 : < 30 μM
dbacp03028 Gageostatin A ELLVDLL Bacillus subtilis Perturbation of the cell membrane Sulforhodamine B (SBR) assay MDA-MB-231 Breast cancer GI50 : 4.6–19.6 μg/mL
dbacp03037 Galaxamide derivative (Compound 3) cyclo(WnMLLLnML) Marine invertebrates Inducing apoptosis MTT assay MD-MBA-231 Breast cancer IC50 :3.51 ± 1.32 μg/Ml
dbacp03041 Galaxamide derivative Compound 1 cyclo(FnMLLLnML) Marine invertebrates Inducing apoptosis MTT assay MD-MBA-231 Breast cancer IC50 : 5.83 ± 0.45 μg/M
dbacp03045 Galaxamide derivative Compound 2 cyclo(NAl-nMLLLnML) Marine invertebrates Inducing apoptosis MTT assay MD-MBA-231 Breast cancer IC50 : 4.48 ± 2.24 μg/mL
dbacp03350 Hylin PL FLGLIPALAGAIGNLIK Skin secretions, the banana tree dwelling frog, Trinidad, South America Membrane disruption Not specified MDA-MB-231 Not found LC50 : < 30 μM
dbacp03353 Hymenochirin-1B KLSPETKDNLKKVLKGAIKGAIVAKMV Zaire dwarf clawed frog Membrane disruption and cell lysis Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay MDA-MB-231 Breast cancer LC50 : 9.0 ± 0.3 μM
dbacp03379 IL-4Rα-lytic hybrid peptide KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK Interleukin-4 receptor a (IL-4Ra) chain Induction of apoptosis WST-1 assay MDA-MB-231 Breast cancer IC50 : 5.7 µMol/L
dbacp03534 L-amino acid oxidase (CC-LAAO) (LAO) (EC 1.4.3.2) MNVFFMFSLLFLAALESCADDKNPLEEEFFEADYEEFLLIAKNGLQQTSNPKRVVIVGAGMSGLSAAYVLAKTGHEVILLEASERVGGRVSTYRNDQEGWYANLGPMRLPERHRIVREYIRKFGLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEKGKSAPQLYRDSLQKIIEEYGRSNCSYILNKYDTYSTKDYLIKEGNLSPGAVDMVGDLLNEDSGYYVSFIESLKPDDIFAYENRFDEIVGGFDKLPTSMYQAIQEKVRLNVRVIKIQQDVKEVTVTYQTPAKNLSYVTADYVIVCTTSGAARRIKFEPPLPLKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSITDRPSRLIHYPNHNFPNGIGVLVIFTIADDADFFLALDNKTIADIVIHDLSLIHQLPKEKIRDLCYVSMIQKWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLTAARDVNRASENPSGIHLSNDNEL Horned desert vip Cytotoxic effects MTT assay MDA-MB-231 Not found IC50 : 6 µg/mL
dbacp04132 LK1 (Temporin-1CEa Analog peptide) FVDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 66.4µM
dbacp04135 LK2(5) (Temporin-1CEa Analog peptide) FKDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 894.7 µM
dbacp04138 LK2(6) (Temporin-1CEa Analog peptide) FVKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 85.41 µM
dbacp04141 LK2(6)A(L) (Temporin-1CEa Analog peptide) FVKLKKILNIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 34.74 µM
dbacp04144 LK2(6)AN(2L) (Temporin-1CEa Analog peptide) FVKLKKILNIILSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 41.55 µM
dbacp04147 LK3 (Temporin-1CEa Analog peptide) FKKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MDA-MB-231 Breast cancer IC50 : 224.8 µM
dbacp04353 Lytic KLlLKlLkkLLKlLKKK Interleukin-4 receptor a (IL-4Ra) chain Induction of apoptosis WST-1 assay MDA-MB-231 Breast cancer IC50 : 18.5 µMol/L
dbacp04357 Lytic KLlLKlLkkLLKlLKKK Transferrin receptor (TfR) Disintegration of cell membrane WST-1 assay MDA-MB-231 Breast cancer IC50 : 27.0 µM
dbacp04564 Mastoparan INLKALAALAKKIL Venom base Inducing apoptosis Not specified MDA-MB-231 Not specified IC50 : 251.25 ± 11.5 µM
dbacp04828 Neuropilin-1 MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQAPDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLFIKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFVPKMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSYINEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSFEGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGDKNISRKPGNVLKTLDPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYNFELVDGVKLKKDKLNTQSTYSEA Human Can affect tumor cells directly in an autocrine manner Proliferation and chemotaxis assays 231 Breast carcinoma Not found
dbacp04909 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 5 µM
dbacp04910 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 10 µM
dbacp04911 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 30-35% Cytotoxic at 25 µM
dbacp04912 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 60% Cytotoxic at 50 µM
dbacp04932 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 5 µM
dbacp04933 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 10 µM
dbacp04934 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 30-35% Cytotoxic at 25 µM
dbacp04935 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 60% Cytotoxic at 50 µM
dbacp04954 NRC-07 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer ~0% Cytotoxic at 5 µM
dbacp04955 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 10 µM
dbacp04956 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 20-30% Cytotoxic at 25 µM
dbacp04957 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 40-50% Cytotoxic at 50 µM
dbacp04977 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer ~5% Cytotoxic at 10 µM
dbacp04978 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 10% Cytotoxic at 25 µM
dbacp04979 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 10-15% Cytotoxic at 50 µM
dbacp05079 p53-C terminal peptide GSRAHSSHLKSKKGQSTSRHKK Not found Inducing apoptosis Annexin V-FITC Binding assay MDA-MB-231 Breast cancer Not found
dbacp05103 PA10 RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05107 PA15 RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05111 PA2 RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05115 PA3 RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05119 PA38 RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05123 PA49 RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MDA-MB231 Breast cancer MIC : 10 μM
dbacp05439 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay MDA-MB-231 Breast cancer At 100 µM 55% viablity
dbacp05509 Phylloseptin-1.1TR (PLS-1.1TR) FLSLIPKIAGGIASLVKNL Trinidad leaf frog Cytotoxic Cell viability assay MDA‐MB231 Not found LC50 : 20 μM
dbacp05512 Phylloseptin-1.2TR (PLS-1.2TR) (Phylloseptin-1.3TR) FLSLIPKIAGGIASLVKDL Trinidad leaf frog Cytotoxic Cell viability assay MDA‐MB231 Not found Not found
dbacp05515 Phylloseptin-2.1TR (PLS-2.1TR) (Phylloseptin-2.2TR) FLSLIPHIATGIAALAKHL Trinidad leaf frog Cytotoxic Cell viability assay MDA‐MB231 Not found LC50 : 24 μM
dbacp05518 Phylloseptin-3.1TR (PLS-3.1TR) (Phylloseptin-3.3TR) FFSMIPKIATGIASLVKNL Trinidad leaf frog Cytotoxic Cell viability assay MDA‐MB231 Not found LC50 : 18 μmolL−1
dbacp05521 Phylloseptin-3.2TR (PLS-3.2TR) FFSMIPKIATGIASLVKDL Trinidad leaf frog Cytotoxic Cell viability assay MDA‐MB231 Not found Not found
dbacp05532 Phylloseptin-PBa1 FLSLIPHIASGIASLVKNF Burmeister's leaf frog, Brazil, South America Disruption of cell membranes MTT cell viability assay MB231 Breast cancer IC50 : approx. 0.29 µM
dbacp05543 Phylloseptin-PBa2 FLSLLPHIASGIASLVSKF Burmeister's leaf frog, Brazil, South America Disruption of cell membranes MTT cell viability assay MB231 Breast cancer IC50 : approx. 0.50 µM
dbacp05556 Picturin 1BN GIFKDTLKKVVAAVLTTVADNIHPK Norepinephrine-stimulated skin secretion, the Giant Gladiator Treefrog, the Rusty Treefrog, Trinidad, South America Cell membrane penetration Not specified MDA-MB-231 Breast adenocarcinoma LC50 : 7 - 14 µM
dbacp05559 Picturin 2BN GLMDMLKKVGKVALTVAKSALLP Norepinephrine-stimulated skin secretion, the Giant Gladiator Treefrog, the Rusty Treefrog, Trinidad, South America Cell membrane penetration Not specified MDA-MB-231 Breast adenocarcinoma LC50 : 7 - 14 µM
dbacp05677 Ps-1Pb IKIPSFFRNILKKVGKEAVSLIAGALKQS Merlin's dwarf gray frog Immunomodulatory properties Cytotoxicity assays, CellTiter-Glo Luminescent cell viability assay MDA-MB-231 Breast adenocarcinoma LC50 : < 12 μM
dbacp05680 Ps-2Pa GIFPIFAKLLGKVIKVASSLISKGRTE Merlin's dwarf gray frog Immunomodulatory properties Cytotoxicity assays, CellTiter-Glo Luminescent cell viability assay MDA-MB-231 Breast adenocarcinoma LC50 : < 12 μM
dbacp05761 PUMA BH3 LRRMADDLN BH3-only, Direct activators (PUMA, Bid) Inducing apoptosis Not specified MDA-MB-231 Colon cancer Not found
dbacp05864 RA-V cyclopeptideRA-V-,cyclo(YAAYAY) Plant sources Inducing apoptosis MTT assay MDA-MB-231 Breast cancer Not found
dbacp05915 Raniseptin PL GVFDTVKKIGKAVGKFALGVAKNYLNS Skin secretions, the banana tree dwelling frog, Trinidad, South America Membrane disruption Not specified MDA-MB-231 Not found LC50 : < 30 μM
dbacp06212 TAT-DV3-BH3 YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY BH3-only, Direct activators (PUMA, Bid) Inducing apoptosis CCK-8 assay MDA-MB-231 Colon cancer Survival rate : 69.79 ± 6.71%
dbacp06231 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MDA-MB-231 Breast cancer 22% cell viability at 40 µM
dbacp06232 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption LDH leakage assay MDA-MB-231 Breast cancer 61% cytotoxicity at 40 µM
dbacp06235 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MDA-MB-231 Breast cancer MIC : 40 µM
dbacp06236 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption LDH leakage assay MDA-MB-231 Breast cancer MIC : 40 µM
dbacp06326 Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 RRRQRRKKRGGGGLGASWHRPDK Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH3 Apoptosis inducing Cell viability assay, Transwell invasion assay MDA-MB-231 Breast cancer Not specified
dbacp06332 Transferrin receptor (TfR)-lytic hybrid peptide THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK Transferrin receptor (TfR) Disintegration of cell membrane WST-1 assay MDA-MB-231 Breast cancer IC50 : 7.8 µM
dbacp06458 Varv peptide A (Varv A; Plant defensin) GLPVCGETCVGGTCNTPGCSCSWPVCTRN Field pansy Not specified Nonclonogenic fluorometric microculture assay MDA-MB-231 Not found IC50 : > 10 µg/mL
dbacp06468 Varv peptide E (Varv E; Plant defensin) GLPICGETCVGGTCNTPGCSCSWPVCTRN Field pansy Not specified SRB assay MDA-MB-231 Not found IC50 : > 10 µg/mL
dbacp06478 Varv peptide F (Varv F; Plant defensin) GVPICGETCTLGTCYTAGCSCSWPVCTRN Field pansy Not specified Not specified MDA-MB-231 Not found IC50 : > 10 µg/mL
dbacp06484 Varv peptide H (Varv H; Plant defensin) GLPVCGETCFGGTCNTPGCSCETWPVCSRN Field pansy Not specified Nonclonogenic fluorometric microculture cytotoxicity assay MDA-MB-231 Leukemia IC50 : >10 µg/mL
dbacp06615 LA3IK LAIAVK Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MDA-MB-231 Breast Cancer IC50 = 223.6 ± 5.62 µM
dbacp06619 D-LA3IK laiavk Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MDA-MB-231 Breast Cancer IC50 = 197.72 ± 5.42 µM
dbacp06623 LA3IK-SCR LAKAVI Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MDA-MB-231 Breast Cancer IC50 = 243 ± 8.16 µM
dbacp06627 RP-7 RPPCVIL Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MDA-MB-231 Breast Cancer IC50 = 139.03 ± 8.41 µM
dbacp06631 D-RP-7 rppcvil Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MDA-MB-231 Breast Cancer IC50 = 95 ± 7.71 µM
dbacp06635 RP7 SCR RPPLVIC Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MDA-MB-231 Breast Cancer IC50 = 156 ± 8.15 µM
dbacp06743 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay MDA-MB-231 Breast Cancer IC50 = 18.15 µM
dbacp06757 ATMP5 THPPTTTTTTTTTTTYTAAPATTT Synthetic Analog of ATMP1 Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 64.04 ± 0.021 μg /ml
dbacp06758 ATMP1 THPPTTTTTTTTTTTYTAAPATTT Anabas testudineus Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 8.25 ± 0.14 μg/ml
dbacp06761 RP7 ATRQPNH RAGE(receptor for advanced glycation end product) inhibitor Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 24.5 µM
dbacp06763 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay MDA-MB-231 Breast Cancer IC50 = 24.25 µM
dbacp06771 Moricin AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA Bombyx mori Peptide-induced cell death MTT assay MDA-MB-231 Triple-negative Breast Cancer 70% cell viability at 6.25 µg/ml
dbacp06772 Moricin AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA Bombyx mori Peptide-induced cell death LDH release assay MDA-MB-231 Triple-negative Breast Cancer Significant decrease in cell viability at 6.25 μg/ml
dbacp06773 Moricin AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA Bombyx mori Peptide-induced cell death Trypan blue assay MDA-MB-231 Triple-negative Breast Cancer 70% cell viability at 6.25 µg/ml
dbacp06799 Test peptide YSFGL Neuropep Peptide Not available MTT assay MDA-MB-231 Lung Cancer IC50 = 39.047±0.770 µM
dbacp06800 A11 EYVQTVKSSKG Annexin A1 Targeting PD-L1 Biotin Pull Down assay MDA-MB-231 Breast Cancer Not Available
dbacp06842 Api8-NH2 UGLUGGLZGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 > 20 µM
dbacp06843 Leu4-NH2 UGLLGGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 > 20 µM
dbacp06844 K2569-Lol UKLUKKLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 = 12 µM
dbacp06845 K259-NH2 UKLUKGLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =13 µM
dbacp06846 K259-Lol UKLUKGLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =10 µM
dbacp06847 K25-Lol UKLUKGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =9 µM
dbacp06848 K56-Lol UGLUKKLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =12 µM
dbacp06849 K6-NH2 UGLUGKLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =8 µM
dbacp06850 K2-NH2 UKLUGGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 = 9 µM
dbacp06869 LfcinB(21-25)Pal RWQWRWQWR LfcinB Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 103 µM
dbacp06872 RR-1-RR RRWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 67 µM
dbacp06874 R-1-RR RWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 95 µM
dbacp06876 RR-1-R RRWQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 73 µM
dbacp06878 1 WQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 170 µM
dbacp06880 R-1 RWQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 150 µM
dbacp06882 1-R WQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 150 µM
dbacp06910 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay MDA-MB-231 Breast Cancer 33.6% decrease in cell viability at 10 μM
dbacp06922 Ocellatin-3N GIFDVLKNLAKGVITSLAS Leptodactylus nesiotus Not available CellTiter-Glo assay MDA-MB-231 Breast Cancer LC50 = 51 ± 16 μM
dbacp07015 NAF-1 FLGVLALLGYLAVRPFLPKKKQQK NAF-1/CISD2 Mitochondria-ER targeting, induces multimodal death. Not Available MDA-MB-231 Breast Cancer IC50 = 18.3 ± 0.4 μM
dbacp07016 D-NAF-1 flgvlallgylavrpflpkkkqqk NAF-1/CISD2 Mitochondria-ER targeting, induces multimodal death. Not Available MDA-MB-231 Breast Cancer IC50 = 12.8 ± 0.2 μM
dbacp07088 HB43 FAKLLAKLAKKLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay MDA-MB-231 Breast Cancer 50% cell viability at 20 μM
dbacp07092 HB43-mut2 FAKLLAKLAKLLK Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay MDA-MB-231 Breast Cancer 80% cell viability at 20 μM
dbacp07096 HB43-mut3 FAKLLAKLARRLL Synthetic Motif-driven membrane insertion triggers cytotoxicity AlamarBlue assay MDA-MB-231 Breast Cancer 75% cell viability at 20 μM
dbacp07111 LyeTx-I-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Synergistic autophagic death via AKT inhibition. MTT assay MDA-MB-231 Breast Cancer IC50 = 2.47 µM
dbacp07115 Galaxamide (N-Me-L)L(N-Me-L)LL Galaxaura filamentosa Cell-cycle arrest induces apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 8.73 ± 0.29 µg/ml
dbacp07119 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 17.81 ± 0.6 µg/ml
dbacp07284 AtMP1 THPPTTTTTTTTTTTTTAAPATTT Anabastestudineus skin mucus fraction 2 p53-mediated Bax/Bcl-2 apoptosis activation MTT assay MDA-MB-231 Breast Cancer IC50 = 9.35 ± 0.25 μg/ml
dbacp07286 AtMP2 TGIATSGLATFTLHTGSLAPAT Anabastestudineus skin mucus fraction 2 p53-mediated Bax/Bcl-2 apoptosis activation MTT assay MDA-MB-231 Breast Cancer IC50 = 6.97 ± 0.24 μg/ml
dbacp07301 vCPP0769 RRLTLRQLLGLGSRRRRRSR Capsid protein of the Torque teno douroucouli virus Dual anticancer and BBB-blockade. MTT assay MDA-MB-231 Breast Cancer IC50 = 9.0 ± 0.1 μM
dbacp07305 vCPP2319 WRRRYRRWRRRRRWRRRPRR Capsid protein of the Torque teno douroucouli virus Dual anticancer and BBB-blockade. MTT assay MDA-MB-231 Breast Cancer IC50 = 4.5 ± 0.1 μM
dbacp07311 LyeTxI-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Apoptosis induction and immune modulation. MTT assay MDA-MB-231 Breast Cancer IC50 = 5.77 ± 0.83 µM
dbacp07367 Piscidin 3 FIHHIFRGIVHAGRSIGRFLTG Morone chrysops x Morone saxatilis Cu²⁺-mediated membrane lipid oxidation MTT assay MDA-MB-231 Breast Cancer IC50 = 17.5 µM
dbacp07368 Piscidin 3 FIHHIFRGIVHAGRSIGRFLTG Morone chrysops x Morone saxatilis Cu²⁺-mediated membrane lipid oxidation MTT assay MDA-MB-231 Breast Cancer IC50 = 5.25 µM
dbacp07412 Si1 (KLAKLAK)2 Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 746.5 ± 7.6 µM
dbacp07415 Si2 KL(Beta-A)KL(Beta-A)K Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 840 ± 21.18 µM
dbacp07416 Si11 KL(Beta-A)KL(Beta-A)K Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 1087 ± 70.71 µM
dbacp07420 Si14 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 1049 ± 49.77 µM
dbacp07422 Si15 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 346.3 ± 7.91 µM
dbacp07476 Latcripin-7A MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE Lentinula edodes Cell-cycle arrest, apoptosis, autophagy induction CCK-8 assay MDA-MB-231 Breast Cancer IC50 = 122 μg/mL
dbacp07489 LRH7-G5 Not Available Synthetic GPR1 antagonism, PI3K/AKT inhibition MTT assay MDA-MB-231 Breast Cancer 60% cell viability at 0.01 μM
dbacp07495 RA-3 RWrGGGGGLFDIIKKIAESF Synthetic Integrin-targeting, α-helix mediated lysis MTT assay MDA-MB-231 Breast Cancer IC50 = 28.4 μM
dbacp07865 R-Lycosin I derivative 8a RGWFRAMRSIARFIARERLRGHL Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I GLUT1-mediated uptake enhances cytotoxicity CCK-8 assay MDA-MB-231 Breast Cancer IC50 = 10.1 ± 0.2 µM
dbacp07871 R-Lycosin I derivative 8b RGWFRAMRSIARFIARERLRGHL Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I GLUT1-mediated uptake enhances cytotoxicity CCK-8 assay MDA-MB-231 Breast Cancer IC50 = 6.0 ± 0.2 µM
dbacp07932 myristoyl-CM4 GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI Bombyx mori Enhanced binding, mitochondrial dysfunction, apoptosis MTT assay MDA-MB-231 Breast cancer IC50 = 4 μM
dbacp07937 Pantinin-1 GILGKLWEGFKSIV Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 28.5 ± 1.0 µM
dbacp07939 Pantinin-2 IFGAIWKGISSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 12.5 ± 1.0 µM
dbacp07941 Pantinin-3 FLSTIWNGIKSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 13.5 ± 2.0 µM
dbacp08048 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay MDA-MD-231 Breast Cancer ED50 = 5.6 μM
dbacp08052 Poca A GLPCAESCVFIPCTITAILGCSCRDRVCYD Pombalia calceolaria Cyclotides induce cytotoxicity, inhibit migration MTS assay MDA-MB-231 Breast Cancer IC50 = 1.8 μM
dbacp08053 Poca B GIPCAESCVFIPCVTAILGCSCKDVCYN Pombalia calceolaria Cyclotides induce cytotoxicity, inhibit migration MTS assay MDA-MB-231 Breast Cancer IC50 = 2.7 μM
dbacp08054 CyO4 GIPCGESCVWIPCISSAIGCSCKNKVCYRN Viola odorata Cyclotides induce cytotoxicity, inhibit migration MTS assay MDA-MB-231 Breast Cancer IC50 = 9.8 μM
dbacp08077 PvD1 KTCENLADTYKGPCFTTGSCDDHCKNKEHLRSGRCRDDFRCWCTKNC Phaseolus vulgaris Disrupts tumor cells MTT assay MDA-MB-231 Breast Cancer IC50 = 0.82 ± 0.14 µM
dbacp08112 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 3.15 μM
dbacp08116 FR4P FRRPFKWFRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 6.3 μM
dbacp08120 FR8P FRRFFKWPRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 6.4 μM
dbacp08124 FR11P FRRFFKWFRRPFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 7 μM
dbacp08128 FR4,8P FRRPFKWPRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 15.4 μM
dbacp08132 FR8,11P FRRFFKWPRRPFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay MDA-MB-231 Breast Cancer IC50 = 27 μM
dbacp08147 Bothropoidin Not Available Bothrops pauloensis snake venom Bothropoidin inhibits breast cancer progression MTT assay MDA-MB-231 Breast Cancer 30% cytotoxicity at 100 μg/mL
dbacp08148 Bothropoidin Not Available Bothrops pauloensis snake venom Bothropoidin inhibits breast cancer progression Apoptosis assay MDA-MB-231 Breast Cancer Early apoptosis at 10 μg/mL and Late apoptosis at 40 μg/mL
dbacp08149 Bothropoidin Not Available Bothrops pauloensis snake venom Bothropoidin inhibits breast cancer progression Cell migration assay MDA-MB-231 Breast Cancer Inhibited cell migration by 45% at 10 μg/mL
dbacp08296 BnSP-6 SLFELGKMILQETGKNPAKSYGAYGCNCGVLGRGGPKDATDRCCYVHKCCYKKLTGCDPKKDRYSYSWKDKTIVCGENNPCLKELCECDKAVAICLRENLGTYNKKYRYHLKPFCKKADPC B. pauloensis Not Available MTT assay MDA-MB-231 Breast Cancer 45% cell cytotoxicity at 100 μg/mL
dbacp08300 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MDA-MB-231 Breast Cancer IC50 = 212 ± 0.5 µM
dbacp08331 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 MDA-MB-231 Breast Cancer Cell Viability = 62.3% at 25 μM
dbacp08339 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 MDA-MB-231 Breast Cancer Cell Viability = 81.7% at 25 μM
dbacp08425 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay MDA-MB-231 Breast Cancer IC50 = 0.8061 μM
dbacp08429 hBD3-3 M1 GKCSTRGRKCMRRKK Synthetic Not Available Cell Proliferation assay MDA-MB-231 Breast Cancer Concentration dependent reduction in colony formation between 100 μM and 200 μM.
dbacp08430 hBD3-3 M1 GKCSTRGRKCMRRKK Synthetic Not Available Annexin V/ PI staining assay MDA-MB-231 Breast Cancer Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group
dbacp08431 hBD3-3 M2 GKCSTRGRKMCRRKK Synthetic Not Available Cell Proliferation assay MDA-MB-231 Breast Cancer Concentration dependent reduction in colony formation between 100 μM and 200 μM.
dbacp08432 hBD3-3 M2 GKCSTRGRKMCRRKK Synthetic Not Available Annexin V/ PI staining assay MDA-MB-231 Breast Cancer Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group
dbacp08439 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting MDA-MB-231 Breast Cancer IC50< 20 nM